BiotechTube

CTx-1301 - Dexmethylphenidate 6.25mg + CTx-1301 - Dexmethylphenidate 12.5mg + CTx-1301 - Dexmethylphenidate 18.75mg + CTx-1301 - Dexmethylphenidate 25.0mg + CTx-1301 - Dexmethylphenidate 31.25mg + CTx-1301 - Dexmethylphenidate 37.5mg + Placebo

Phase 3Active
0 views this week 0 watching💤 Quiet
Interest: 34/100
34
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
4
Phase 3
5
Approved
Indication / Disease

ADHD

Conditions

ADHD, ADHD - Combined Type, Attention Deficit Hyper Activity, Attention Deficit Hyperactivity Disorder, Attention Deficit Disorder With Hyperactivity, Attention Deficit Hyperactivity Disorder Combined, Attention-deficit Hyperactivity

Trial Timeline

Jul 31, 2023 → Mar 1, 2026

NCT ID
NCT05924594

About CTx-1301 - Dexmethylphenidate 6.25mg + CTx-1301 - Dexmethylphenidate 12.5mg + CTx-1301 - Dexmethylphenidate 18.75mg + CTx-1301 - Dexmethylphenidate 25.0mg + CTx-1301 - Dexmethylphenidate 31.25mg + CTx-1301 - Dexmethylphenidate 37.5mg + Placebo

CTx-1301 - Dexmethylphenidate 6.25mg + CTx-1301 - Dexmethylphenidate 12.5mg + CTx-1301 - Dexmethylphenidate 18.75mg + CTx-1301 - Dexmethylphenidate 25.0mg + CTx-1301 - Dexmethylphenidate 31.25mg + CTx-1301 - Dexmethylphenidate 37.5mg + Placebo is a phase 3 stage product being developed by Cingulate for ADHD. The current trial status is active. This product is registered under clinical trial identifier NCT05924594. Target conditions include ADHD, ADHD - Combined Type, Attention Deficit Hyper Activity.

What happened to similar drugs?

10 of 20 similar drugs in ADHD were approved

Approved (10) Terminated (2) Active (10)
✅atomoxetineEli LillyApproved
✅Strattera (atomoxetine)Eli LillyApproved
✅Atomoxetine + placeboEli LillyApproved
✅Atomoxetine Hydrochloride + placeboEli LillyApproved
✅atomoxetine (Strattera)Eli LillyApproved
🔄dasotraline + PlaceboSumitomo PharmaPhase 3
🔄dasotraline 4mgSumitomo PharmaPhase 3

Hype Score Breakdown

Clinical
17
Activity
12
Company
5
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT05924594Phase 3Active

Competing Products

20 competing products in ADHD

See all competitors
ProductCompanyStageHype Score
atomoxetineEli LillyApproved
39
Strattera (atomoxetine)Eli LillyApproved
43
Atomoxetine + placeboEli LillyApproved
43
Atomoxetine Hydrochloride + placeboEli LillyApproved
43
atomoxetine (Strattera)Eli LillyApproved
43
Atomoxetine + stimulants (any approved ADHD medication)Eli LillyPre-clinical
26
dasotraline + PlaceboSumitomo PharmaPhase 3
40
dasotralineSumitomo PharmaPhase 1
29
dasotraline 4mgSumitomo PharmaPhase 3
40
AZD1446 + AZD1446 + AZD1446 + PlaceboAstraZenecaPhase 2
35
Placebo + AZD3480 + AZD3480AstraZenecaPhase 2
35
MK0249 + Concerta (methylphenidate) + PlaceboMerckPhase 2
35
Focalin XRNovartisPhase 3
40
Dex-Methylphenidate hydrochloride Extended Release (Focalin® XR) + PlaceboNovartisApproved
43
Dexmethylphenidate HCl extended-release capsulesNovartisPhase 3
40
Methylphenidate hydrochlorideNovartisPhase 3
40
Focalin XRNovartisPhase 3
40
methylphenidate HCl ERCT + PlaceboPfizerApproved
35
methylphenidate HCl ERCTPfizerApproved
35
Very Low Dose Quillivant XR + Low Dose Quillivant XR + Moderate Dose Quillivant XRPfizerApproved
43